i
A Second Generation Pneumococcal Conjugate Vaccine for Prevention of Pneumococcal Diseases in Children
-
Feb 2011
Source: Curr Opin Pediatr. 23(1):98-104. -
Alternative Title:Curr Opin Pediatr
-
Publisher's site:
-
Personal Author:
-
Description:Purpose
A second generation 13 valent pneumococcal conjugate vaccine (PCV13) was licensed and recommended for universal immunization of children through age five years in 2010. Its introduction is intended to address the residual burden of pneumococcal diseases that persists a decade after the introduction of PCV7.
Recent Findings
Immunization with PCV7 has resulted in a substantial decline in pneumococcal diseases caused by vaccine serotypes in both vaccinated and unvaccinated persons in the US. However an increase in disease due to non vaccine serotypes, including empyema; the emergence of multidrug, including ceftriaxone, resistant serotype 19A strains; and the need for broader serotype coverage to address the global disease burden provides a rationale for a second generation conjugate vaccine that includes serotypes 1, 3, 5, 6A, 7F and 19A.
Summary
This article reviews the lessons learned from a decade of experience with PCV7, the increasing problem of disease due to non-vaccine serotypes, and the likelihood of PCV13 to impact the residual disease burden. We contrast the potential differences in prevention of invasive pneumococcal disease (IPD) compared to nonbacteremic pneumonia and acute otitis media. We conclude with the current recommendations for PCV13 providing a rationale for immunization through age 5 years to create both direct and indirect protection in the population.
-
Subject:
-
Source:
-
Pubmed ID:21191300
-
Pubmed Central ID:PMC3357900
-
Document Type:
-
Funding:
-
Collection(s):
-
Main Document Checksum:
-
File Type:
-
txt 
gif 
jpeg 
gif 
jpeg 
gif 
jpeg
[PDF-451.43 KB]
Details:
Supporting Files
More +
Email
CDC-INFO
